News

Article

New Reactor Technology Enables Larger Scale Manufacture of Fragile Cells

Matthieu Egloff, product director with ATMI LifeSciences, discusses the need for larger, special reactors that can provide the necessary conditions for the production of fragile cells on a larger scale.

 

As the demand for larger amounts of stem cells and other fragile cells grows, biopharmaceutical companies are struggling with how to effectively produce these specialized biological materials in larger quantities. ATMI LifeSciences has developed a new reactor to meet that need. Product Director Matthieu Egloff spoke with the

Pharmaceutical Sciences, Manufacturing & Marketplace Report

about the special conditions required for the larger-scale production of fragile cells and how its new Xpansion reactor was designed to provide them.

 

A written version of the interview also may be found

here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com